LC-MS/MS method for quantification of dupilumab in human serum using Protein G enrichment
Journal of Pharmaceutical and Biomedical Analysis · 2027-01 · 283 · 117752
DOI: 10.1016/j.jpba.2026.117752 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2027-01. Verfasst von Kun Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry, Antibodies, Monoclonal. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Chinese Pharmaceutical Association, Zhongnan Hospital of Wuhan University, Bethune Charitable Foundation.
Abstract (Originalsprache)
Dupilumab, a monoclonal antibody targeting IL-4Rα, is used for the treatment of type 2 inflammatory diseases. Recent studies have revealed a nonlinear relationship between its serum concentration and clinical response, particularly a "biological tipping point" during dose interval prolongation, highlighting the need for individualized therapeutic drug monitoring (TDM). In this study, a robust liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for dupilumab quantification in human serum was developed and validated. Specifically, dupilumab was enriched from 50 µL serum using Protein G magnetic beads, followed by denaturation, reduction, alkylation, and tryptic digestion. A surrogate peptide SGQSPQLLIYLGSNR was selected for quantification, and its stable isotope-labeled (SIL) analog served as an internal standard. Separation was performed on an Acquity UPLC BEH C8 column (50 mm × 2.1 mm, 1.7 µm) with detection using positive electrospray ionization in multiple reaction monitoring (MRM) mode. Excellent linearity was achieved from 1.00 to 400 µg/mL (r² > 0.99), with a lower limit of quantification of 1.00 µg/mL. Intra- and inter-run precision (%CV) and accuracy (%Bias) were within 9.27%. The validated method was successfully applied to analyze clinical serum samples. The established LC-MS/MS method provides a reliable alternative to immunoassays, with a wide dynamic range suitable for TDM and personalized dose interval adjustments in patients receiving dupilumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
- Department of Pharmacy, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434000, China.
- Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. Electronic address: liuliang1@whu.edu.cn.
Förderung
- Chinese Pharmaceutical Association
- Zhongnan Hospital of Wuhan University
- Bethune Charitable Foundation
Zitieren
APA
Yang, K., Wu, J., Yang, C., & Liu, L. (2027). LC-MS/MS method for quantification of dupilumab in human serum using Protein G enrichment. Journal of Pharmaceutical and Biomedical Analysis, 283, 117752. https://doi.org/10.1016/j.jpba.2026.117752
Vancouver
Yang K, Wu J, Yang C, Liu L. LC-MS/MS method for quantification of dupilumab in human serum using Protein G enrichment. Journal of Pharmaceutical and Biomedical Analysis. 2027;283:117752. doi:10.1016/j.jpba.2026.117752
BibTeX
@article{Yang2027,
author = {Yang, Kun and Wu, Jianhua and Yang, Chengming and Liu, Liang},
title = {LC-MS/MS method for quantification of dupilumab in human serum using Protein G enrichment},
journal = {Journal of Pharmaceutical and Biomedical Analysis},
year = {2027},
volume = {283},
pages = {117752},
doi = {10.1016/j.jpba.2026.117752}
}
EUVIMED